News
Novo Nordisk’s semaglutide cuts body weight in large-scale trial
Novo Nordisk’s glucagon-like peptide-1 (GLP-1) agonist semaglutide significantly cut body weight in a large-scale trial of adults who are overweight or obese.
You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.
Novo Nordisk’s glucagon-like peptide-1 (GLP-1) agonist semaglutide significantly cut body weight in a large-scale trial of adults who are overweight or obese.